Natalizumab injection
Products billed under this code include Tysabri.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Tysabri.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Tysabri | Biogen Inc. | 64406-0008-01 | 300 | $7,178.10 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $23.927 | −$0.479 | 1 MG | Natalizumab injection | v1, posted September 17, 2026 |
| 3Q26 | $24.406 | +$0.085 | 1 MG | Natalizumab injection | v1, posted September 15, 2026 |
| 2Q26 | $24.321 | −$0.191 | 1 MG | Natalizumab injection | v1, posted September 15, 2026 |
| 1Q26 | $24.512 | +$0.516 | 1 MG | Natalizumab injection | v1, posted September 15, 2026 |
| 4Q25 | $23.996 | −$0.13 | 1 MG | Natalizumab injection | v1, posted September 8, 2026 |
| 3Q25 | $24.126 | −$0.242 | 1 MG | Natalizumab injection | v1, posted March 10, 2026 |
| 2Q25 | $24.368 | +$0.488 | 1 MG | Natalizumab injection | v1, posted March 10, 2026 |
| 1Q25 | $23.88 | −$0.274 | 1 MG | Natalizumab injection | v1, posted December 19, 2025 |
| 4Q24 | $24.154 | +$0.081 | 1 MG | Natalizumab injection | v1, posted June 11, 2025 |
| 3Q24 | $24.073 | −$0.152 | 1 MG | Natalizumab injection | v1, posted June 11, 2025 |
| 2Q24 | $24.225 | −$0.227 | 1 MG | Natalizumab injection | v1, posted March 11, 2025 |
| 1Q24 | $24.452 | −$0.148 | 1 MG | Natalizumab injection | v1, posted December 19, 2024 |
| 4Q23 | $24.60 | −$0.263 | 1 MG | Natalizumab injection | v1, posted October 10, 2024 |
| 3Q23 | $24.863 | +$0.876 | 1 MG | Natalizumab injection | v1, posted June 5, 2024 |
| 2Q23 | $23.987 | +$0.165 | 1 MG | Natalizumab injection | v1, posted February 23, 2024 |
| 1Q23 | $23.822 | −$0.203 | 1 MG | Natalizumab injection | v1, posted December 6, 2023 |
| 4Q22 | $24.025 | −$0.146 | 1 MG | Natalizumab injection | v1, posted June 22, 2023 |
| 3Q22 | $24.171 | +$1.115 | 1 MG | Natalizumab injection | v1, posted June 9, 2023 |
| 2Q22 | $23.056 | −$0.197 | 1 MG | Natalizumab injection | v1, posted December 14, 2022 |
| 1Q22 | $23.253 | +$0.016 | 1 MG | Natalizumab injection | v1, posted June 8, 2022 |
| 4Q21 | $23.237 | −$0.016 | 1 MG | Natalizumab injection | v1, posted June 2, 2022 |
| 3Q21 | $23.253 | +$0.966 | 1 MG | Natalizumab injection | v1, posted June 2, 2022 |
| 2Q21 | $22.287 | −$0.098 | 1 MG | Natalizumab injection | v1, posted March 1, 2022 |
| 1Q21 | $22.385 | – | 1 MG | Natalizumab injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.